Adelaide, Australia.

The ideal city for your life sciences research and expansion.

Adelaide BioMed CityThe A$3.6 billion Adelaide BioMed City (pictured) is a massive cluster of life sciences infrastructure in the heart of the city, combining education, research and clinical care.

It will be home to Australia’s � rst proton therapy unit and by the end of this year it will grow to 2,000 biomedical researchers, 10,000 total sta� and 18,000 daily visitors.

Faster clinical trialsForty-three and a half per cent of R&D costs will be reimbursed in cash to eligible companies with an aggregated annual turnover of less than A$20 million (approx. US$15 million). This Federal Government program covers clinical trials, analytics, study drug manufacture, and other R&D.

All that is required to start a First-in-Human trial in Adelaide is ethics approval, which takes an average of just six weeks, saving six to nine months to start a clinical trial compared to the US or Europe.

Royal Adelaide Hospital

Better manufacturingAutomotive manufacturing has developed a culture which delivers precision products, e� ciently and cost-e� ectively, with a strikingly low defect rate and high traceability.

Adelaide has decades of experience in world’s-best-practice manufacturing in the automotive and defence industries, providing high-skilled workers and a solid supply chain that are now being successfully applied to medical device manufacturing.

Easier sales and marketingAustralia is a bridge to Asia-Paci� c. Take advantage of free trade agreements with Japan, Korea, Malaysia and China.

By locating in Adelaide, businesses can easily manage, train and further grow their national and Asia-Paci� c sales and distribution teams.

Find out more at healthindustries.sa.gov.au/nature

South Australian Health and MedicalResearch Institute 2

South Australian Health and MedicalResearch Institute

The University of Adelaide Health and Medical Sciences Building

University of South Australia Cancer Research Institute

University of South Australia campus

CMAX Phase 1 clinical trials unit